MedTrace Logo

Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer

NCT00268151 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-03-05

No results posted yet for this study

Summary

The purpose of this study is to determine the most suitable dose of Oxaliplatin that can be safely given in combination with a low fixed dose of Capecitabine and a limited volume of radiation in patients with non-small cell lung cancer.

Conditions

  • Carcinoma, Non-Small Cell Lung

Interventions

DRUG

Oxaliplatin

DRUG

Capecitabine

Sponsors & Collaborators

  • James Graham Brown Cancer Center

    collaborator OTHER

  • Sanofi

    collaborator INDUSTRY

  • University of Louisville

    lead OTHER

Principal Investigators

  • Goetz H Kloecker, MD, MSPH · James Graham Brown Cancer Center/ University of Louisville

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00268151 on ClinicalTrials.gov